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Abstract
 
Highly polarized type 2 cytokine responses can be harmful and even lethal to the host if they
are too vigorous or persist too long. Therefore, it is important to elucidate the mechanisms that
down-regulate these reactions. Interleukin (IL)-13 has emerged as a central mediator of T
helper cell (Th)2-dominant immune responses, exhibiting a diverse array of functional activi-
ties including regulation of airway hyperreactivity, resistance to nematode parasites, and tissue
remodeling and fibrosis. Here, we show that IL-13 receptor (R)
 
 
 
2 is a critical down-regula-
tory factor of IL-13–mediated tissue fibrosis induced by the parasitic helminth 
 
Schistosoma man-
soni
 
. IL-13R
 
 
 
2 expression was induced after the onset of the fibrotic response, IL-10, IL-13,
and Stat6 dependent, and inhibited by the Th1-inducing adjuvant IL-12. Strikingly, schisto-
some-infected C57BL/6 and BALB/c IL-13R
 
 
 
2–deficient mice showed a marked exacerba-
tion in hepatic fibrosis, despite displaying no change in granuloma size, tissue eosinophilia, or
mastocytosis. Fibrosis increased despite the fact that IL-13 levels decreased significantly in the
liver and serum. Importantly, pathology was prevented when IL-13R
 
 
 
2–deficient mice were
treated with a soluble IL-13R
 
 
 
2-Fc construct, formally demonstrating that their exacerbated
fibrotic response was due to heightened IL-13 activity. Together, these studies illustrate the
central role played by the IL-13R
 
 
 
2 in the down-regulation of a chronic and pathogenic Th2-
mediated immune response.
Key words: ﬁbrosis • inﬂammation • liver • granuloma • mouse
 
Introduction
 
Type 2 cytokines including IL-4, IL-10, and IL-13 are of-
ten described as antiinflammatory mediators because they
inhibit type 1–dominated cell-mediated immune responses
(1). Nevertheless, studies of allergy, asthma, and the re-
sponse to extracellular helminths clearly demonstrate that
many type 2 cytokines can also act as proinflammatory me-
diators (2). Indeed, several recent studies have demon-
strated that highly polarized immune responses may be-
come detrimental or even lethal to the host if they are too
vigorous or become chronic, regardless of whether type 1
or type 2 cytokines dominate the response (3–5). In each
case, however, distinct forms of immune-mediated pathol-
ogy develop as a consequence of sustained cytokine pro-
 
duction (6, 7). Therefore, understanding the various
control mechanisms that suppress or inhibit chronic in-
flammatory reactions is of utmost importance.
In schistosomiasis, a chronic inflammatory disease of the
liver and gut, Th2 cytokines are required for normal granu-
loma formation and development of hepatic fibrosis (8). In-
deed, several studies have shown that type 1 cytokines re-
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duce fibrotic pathology whereas Th2 cytokines play critical
roles in the pathogenesis of the disease (5, 9–12). Develop-
ment of the Th2 response is highly dependent upon IL-4
and IL-4 receptor expression (13, 14) whereas IL-10 ap-
pears to act as a potent immunosuppressive cytokine, re-
ducing both type 2 cytokine production and granuloma-
tous inflammation (5, 15). Notably, however, recent
studies suggested an even more critical role for IL-13, re-
vealing it as the key mediator of the fibrotic response (11,
12), the primary cause of morbidity and mortality in hu-
man schistosomiasis (16). IL-13 is highly abundant during
schistosome infection and is produced at levels far exceed-
ing IL-4, approaching 100-fold more (11). Thus, although
both cytokines utilize the IL-4R
 
  
 
chain for signaling and
exhibit similar functional activities, IL-13 plays a more im-
portant role in the pathogenesis of fibrosis. Consistent with
this conclusion, studies conducted in related models also
demonstrated critical roles for IL-13 in resistance to gas-
trointestinal nematode infection (17–19), tumor immuno-
surveillance (20), and in the pathogenesis of asthma (21–
23). Therefore, a better understanding of the mechanisms
that control the production and/or activity of IL-13 in vivo
is particularly important.
Many similarities and differences in function between
IL-4 and IL-13 might be explained by the organization of
the receptor complex that binds these cytokines. The most
accepted model for the IL-4–IL-13 receptor complex sug-
gests there are at least three different receptor combina-
tions. The type I receptor is composed of the common IL-
2R
 
  
 
chain (
 
 
 
c; reference 24) and the unique IL-4R
 
 
 
chain, with the latter serving as the signaling receptor.
There is also a type II IL-4R, which is composed of the IL-
4R
 
  
 
and IL-13R
 
 
 
1 chains (25, 26). The type I receptor,
found mainly on hematopoietic cells, binds only IL-4
whereas the type II receptor interacts with IL-4 and IL-13
with high affinity and is found primarily on nonhemato-
poietic cells (26, 27). Recently, a second IL-13R chain, IL-
13R
 
 
 
2 (28), was cloned and characterized in mice (29).
This third receptor can also exist as a soluble receptor and
binds IL-13 exclusively with much higher affinity than the
IL-13R
 
 
 
1 chain. Structural differences between the cyto-
plasmic domains of the IL-13 receptors suggest they are
functionally distinct, raising the possibility that IL-13R
 
 
 
2
is a dominant-negative inhibitor or a decoy receptor for
IL-13 (29–32). The absence of signaling activity combined
with high ligand affinity and high expression levels on cells
such as fibroblasts (33), match the criteria for a decoy re-
ceptor, as originally described for the decoy IL-1R type II
(34). Interestingly, this receptor was recently engineered as
a soluble IL-13R
 
 
 
2-Fc (sIL-13R
 
 
 
2-Fc)
 
*
 
 fusion protein
and has been used successfully to block several functions at-
tributed to IL-13, including fibrogenesis (11), airways hy-
perreactivity (22, 23, 35, 36), and gastrointestinal parasite
expulsion (19, 37)
 
.
 
 Nevertheless, no previous studies have
 
examined the regulation or function of the endogenous IL-
13R
 
 
 
2 in an important Th2-dependent disease model.
In this study, we investigate the regulation and function
of the IL-13R
 
 
 
2 in mice infected with 
 
Schistosoma mansoni
 
.
In initial studies, we examined whether IL-4/IL-13 recep-
tor expression is modulated in the liver after infection. Ad-
ditional studies were conducted in various KO mice to
determine whether type 1/type 2 cytokines regulate IL-
13R
 
 
 
2 mRNA and protein expression in vivo. Finally,
mice with targeted deletion of the IL-13R
 
 
 
2 (38) were in-
fected with the parasite to determine whether the endoge-
nous IL-13R
 
 
 
2 exhibits either inhibitory or stimulatory
activities during a chronic Th2-dominant immune re-
sponse. Our results show that IL-4R
 
  
 
and IL-13R
 
 
 
2 are
differentially regulated in the liver during the course of 
 
S.
mansoni
 
 infection. Moreover, we show that IL-13R
 
 
 
2 is
regulated by its own ligand, IL-13. Finally, and perhaps of
most importance, we show that IL-13–dependent liver fi-
brosis increases dramatically in the absence of the IL-
13R
 
 
 
2, despite the fact that local Th2 cytokine production
is simultaneously decreased. As such, these results reveal an
important decoy function for the IL-13R
 
 
 
2 and illustrate
how IL-13 receptor expression may significantly alter the
development of type 2 cytokine-dependent pathology.
 
Materials and Methods
 
Animals, Parasite Infections, and Antigen Preparations.
 
6–8-wk-
old female C57BL/6, BALB/c, and C3H/HeN mice were ob-
tained from the Division of Cancer Treatment, National Cancer
Institute. IL-4, IL-4/IL-10, IL-10, IL-12, IL-10/IL-12–deficient,
and WT C57BL/6 mice were generated as previously described
(39) and obtained from Taconic Farms Inc. Breeding pairs of IL-
13–deficient and WT mice were provided by A. McKenzie
(MRC Laboratory of Molecular Biology, Cambridge, United
Kingdom) and maintained on a 129Ola/C57BL/6 (F2) back-
ground (17). The IL-13R
 
 
 
2–deficient mice were generated as
described (38) and backcrossed onto the C57BL/6 and BALB/c
backgrounds. The IL-13R
 
 
 
2–deficient mice were either pro-
vided by Wyeth-Genetics Institute or shipped directly from The
Jackson Laboratory. Stat6-deficient mice were generated as previ-
ously described (40) and provided by W.E. Paul (NIH, Bethesda,
MD). Age- and sex-matched mice were housed in an NIH
American Association for the Accreditation of Laboratory Animal
Care–approved animal facility. All mice were infected percutane-
ously through the tail with 25
 
–
 
30 cercariae of a Puerto Rican
strain of 
 
S. mansoni
 
 (NMRI) obtained from infected 
 
Biomphalaria
glabrata
 
 snails (Biomedical Research Institute). In some experi-
ments, mice were sensitized with 
 
S. mansoni
 
 eggs extracted from
the livers of infected mice. Sensitization of mice with eggs and
rIL-12 was previously described in detail (41). In brief, groups of
10 mice were injected intraperitoneally with 5,000 eggs on three
occasions separated by 2-wk intervals. Animals were also injected
intraperitoneally with either saline or rIL-12 (0.25 
 
 
 
g/dose) con-
secutively for 5 d beginning on the day of each immunization
and then infected 2–4 wk after the last IL-12 injection. For the
induction of pulmonary granulomas, mice were challenged with
5,000 eggs intravenously. Mice were killed in groups of five on
days 7 and 11 after challenge. Some groups were also treated with
0.25 
 
 
 
g rIL-12 on days 0, 1, 3, 4, and 6. rIL-12 and rIL-13 were
 
*
 
Abbreviations used in this paper:
 
 CCCA, Cincinnati cytokine capture assay;
HPRT, hypoxanthine-guanine phosphoribosyl transferase; SEA, soluble
egg antigen; sIL-13R
 
 
 
2-Fc, soluble IL-13R
 
 
 
2-Fc.T
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provided by Wyeth-Genetics Institute. Soluble egg antigen (SEA)
was purified from homogenized 
 
S. mansoni
 
 eggs, as previously de-
scribed (10). The sIL-13R
 
 
 
2-Fc fusion protein and control-Fc
were prepared as previously described (29) and provided by Wy-
eth-Genetics Institute. In the IL-13 blocking studies, animals
were treated between 6 and 12 wk after infection by intra-
peritoneal injection of 0.5 ml PBS containing 200 
 
 
 
g/mouse sIL-
13R
 
 
 
2-Fc every other day, the optimal dose as determined in
previous studies (42). Animals were perfused at the time of death
to determine worm and tissue egg burdens as previously de-
scribed (10).
 
Histopathology and Fibrosis Measurement.
 
The size of hepatic
granulomas was determined in histologic sections stained by
Wright’s Giemsa stain (Histopath of America). 
 
 
 
30 granulomas
per mouse were included in all analyses. The percentages of eo-
sinophils, mast cells, and other cell types were evaluated in the
same sections. The frequency of mast cells was evaluated on a
scale from 0–4, with 0 being low and 4 being a high frequency.
The number of schistosome eggs in the liver and gut and the col-
lagen content of the liver, determined as hydroxyproline, were
measured as previously described (10). Specifically, hepatic col-
lagen was measured as hydroxyproline by the technique of Berg-
man and Loxley (43) after hydrolysis of a 200-mg portion of liver
in 5 ml of 6 N HCl at 110
 
 
 
C for 18 h. The increase in hepatic
hydroxyproline was positively related to egg numbers in all ex-
periments and hepatic collagen is reported as the increase above
normal liver collagen in micromoles per 10,000 eggs: (infected
liver collagen 
 
  
 
normal liver collagen)/liver eggs 
 
  
 
10
 
 
 
4 
 
or mi-
cromoles per worm pair. Fibrosis was also evaluated histologically
using liver sections stained with picrosirius red. The same indi-
vidual scored all histologic features and had no knowledge of the
experimental design.
 
Isolation and Purification of RNA and RT-PCR.
 
Liver tissues
were homogenized in TRIzol reagent (Invitrogen) using a tissue
polytron (Omni International Inc.) and total RNA was extracted
according to the recommendations of the manufacturer. An RT-
PCR procedure was used to determine relative quantities of
mRNA for several cytokine and cytokine receptor genes after
reverse transcription of 1 
 
 
 
g RNA as previously described (44).
The primers and probes for all genes were published previously
(44), except IL-13R
 
 
 
1: 5
 
 
 
-GCA-GCC-TGG-AGA-AAA-
GTC-GTC-AAT-3
 
  
 
(sense), 5
 
 
 
-ACA-GCG-TCG-GCA-AGA-
ACA-CCA-3
 
  
 
(antisense); IL-13R
 
 
 
2: 5
 
 
 
-ATG-GCT-TTT-
GTG-CAT-ATC-AGA-TGC-T-3
 
  
 
(sense), 5
 
 
 
-CAG-GTG-
TGC-TCC-ATT-TCA-TTC-TAA-T-3
 
  
 
(antisense); 
 
 
 
c chain:
5
 
 
 
-ATG-TCC-AGT-GCG-AAT-GAA-GA-3
 
  
 
(sense), 5
 
 
 
-CTC-
CGA-ACC-CGA-AAT-GTG-TA-3
 
  
 
(antisense); and IL-4R
 
 
 
1:
5
 
 
 
-GAG-TGA-GTG-GAG-TCC-TAG-CAT-C-3
 
  
 
(sense), 5
 
 
 
-
GCT-GAA-GTA-ACA-GAA-CAG-GC-3
 
  
 
(antisense). The PCR
cycles used for each cytokine were as follows: IL-13 (33), IL-4
(34), IL-5 (31), IFN-
 
  
 
(29), IL-13R
 
 
 
1 (28), IL-13R
 
 
 
2 (30), IL-
4R
 
 
 
1 (27), 
 
 
 
c chain (27), and hypoxanthine-guanine phospho-
ribosyl transferase (HPRT; reference 23). The amplified DNA
was analyzed by electrophoresis, Southern blotting, and hybrid-
ization with nonradioactive cytokine-specific probes as previ-
ously described (44). The PCR products were detected using an
enhanced chemiluminescence detection system (Amersham Bio-
sciences). The chemiluminescent signals were quantified using a
flat bed scanner (model 600 ZS; Microtek). Arbitrary densito-
metric units were calculated by dividing the cytokine or cell sur-
face marker OD units by the individual HPRT OD units and
multiplying by 100. In some experiments, real-time PCR was
conducted on an ABI Prism 7900 sequence detection system
 
(Applied Biosystems) using SYBR Green PCR Master Mix after
RT of 1 
 
 
 
g RNA. The amount of PCR product was deter-
mined by the Comparative Ct Method as described by the man-
ufacturer, in which each sample was normalized to HPRT and
expressed as a fold increase or decrease versus unchallenged con-
trols.
 
Western Blot Analysis of IL-13R
 
 
 
2.
 
Sera was diluted with 1
vol cell lysis buffer (Tris-buffered saline [20 mM Tris, 150 mM
NaCl, pH 7.5], 1% Triton X-100, 40 mg of iodoacentamide per
25 ml, 1 tablet protease inhibitor cocktail; Boehringer). Three to
five million BaF3/IL-13R
 
 
 
2 cells were lysed in 1.5 ml lysis
buffer. IL-13R
 
 
 
2 was precipitated with 2.5 
 
 
 
g biotinylated Chi-
nese hamster ovary murine IL-13 and streptavidin agarose beads
(streptavidin coupled to agarose; Pierce Chemical Co.). The aga-
rose beads were washed three times with lysis buffer with NaCl
adjusted to 400 mM followed by two washes with PBS. Samples
were reduced and separated on a 12% SDS-PAGE and then
transferred to polyvinylidene difluoride (NEN Life Science Prod-
ucts) by semi-dry electroblotting. The blot was blocked with
Tris-buffered saline 1% Tween-20/4% BSA and then incubated
with polyclonal rabbit sera to murine IL-13R
 
 
 
2 (5 
 
 
 
g/ml; Wy-
eth-Genetics Institute). Peroxidase-labeled goat anti–rabbit IgG
(1:20,000; Jackson ImmunoResearch Laboratories) was added as
a second step. The blot was developed with enhanced chemilu-
minescence reagents (Amersham Biosciences) and exposed on
Hyperfilm (Amersham Biosciences).
 
In Situ Hybridization.
 
Sections of paraffin-embedded tissue
were deparaffinized with xylene, two changes, 3 min each, and
rehydrated to water. After a rinse in RNase-free water and PBS,
permeabilization was performed by incubation with 0.2% Triton
X-100/PBS for 15 min. After two washes with PBS, the sections
were immersed in 0.1 M Tris and 50mM EDTA, pH 8.0 (Sigma-
Aldrich), prewarmed at 37
 
 
 
C containing 5 
 
 
 
g/ml proteinase K
for 15 min. Proteinase K activities were stopped by 0.1 M gly-
cine/PBS for 5 min followed by a postfixation with 4% parafor-
maldehyde for 3 min and then a PBS rinse. To prevent nonspecific
electrostatic binding of the probe, sections were immersed in
0.25% acetic anhydride and 0.1 M triethanolamine solution, pH
8.0, for 10 min followed by 15 s in 20% acetic acid at 4
 
 
 
C. After
three changes in PBS of 5 min each, sections were dehydrated
through 70, 90, and 100% ethanol, each at 3 min. The sections
were completely air-dried before 40 
 
 
 
l prehybridization buffer
was applied, covered with parafilm, and incubated at 52
 
 C for 30
min to reduce nonspecific binding. Parafilm was removed and 40
 l hybridization buffer containing 5 ng/ l digoxigenin-labeled
probe was applied to each section, recovered with parafilm, and
incubated overnight at 52 C in a humid chamber. To generate
the riboprobes, a 23-nucleotide T7 promoter was added to the 5 
or 3  end to generate the template for making either the antisense
or sense riboprobe. The T7 sequence used was taatacgactcactat-
agggaga. IL-13R 1 (sequence data are available from GenBank/
EMBL/DDBJ under accession no. S8096) 5  probe: ggagtcctcct-
gaaggagccag, 3  probe: ggtcaacacattgcttgttcc, used to generate a
403-bp riboprobe; IL-13R 2 (sequence data are available from
GenBank/EMBL/DDBJ under accession no. NM_008356) 5 
probe: gatcatgccttacagtgtgc, 3   probe: ggagcgaatggagtgaagagg,
used to generate a 450-bp riboprobe; and IL-4R  (sequence data
are available from GenBank/EMBL/DDBJ under accession no.
M29854) 5  probe: ggcggtccaatcagacagatacc, 3  probe: ctcctgc-
ctctgcatcccgttg, used to generate a 463-bp riboprobe.
Parafilm was carefully removed and the sections were placed in
a Biogenex Genomx 6000 automatic staining system. Sections
were washed in 2  SSC/0.1% SDS (both from Sigma-Aldrich) atT
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room temperature, four changes at 5 min each. To ensure only
specific hybridization signal remains, sections were washed in a
high stringency solution containing 0.1   SSC/0.1% SDS at
52 C, two changes at 5 min each. To reduce endogenous peroxi-
dase staining, the sections were incubated in 3% H2O2 for 15 min
followed by three washes in buffer. The probe was detected with
antidigoxigenin antibody conjugated to horseradish peroxidase
complex (Roche) diluted 1:500 in 2% normal sheep serum/0.1%
Triton X-100 for 1 h. The biotinylated complex was amplified
using the Tyramide Amplification System (Biogenex). Sections
were incubated with trichostatin A for 5 min followed by five
washes in buffer. The trichostatin A complex was then amplified
further by an incubation with horseradish peroxidase for 15 min
followed by five washes in buffer. The amplified product was de-
veloped with 3,3 -diaminobenzidine (Vector Laboratories) for 10
min, washed in water, stained briefly with Mayers’ hematoxylin
(Sigma-Aldrich), dehydrated through graded alcohol into xylene,
and mounted in DPX mountant before microscopic examination.
ELISPOT and Cincinnati Cytokine Capture Assay (CCCA).
Single cell suspensions of splenocytes were plated in 24-well
plates (4   106 cells/ml) and stimulated with 20  g/ml SEA. Af-
ter 24 h, cells were harvested and plated (105, 5   104, and 104
cells/well) in 96-well plates previously coated with different cy-
tokine-specific Abs at a final concentration of 10  g/ml (anti–
IFN- , anti–IL-4, anti–IL-5, or anti–IL-13) and subsequently
blocked with 5% FCS. Cells were incubated overnight at 37 C in
an atmosphere of 5% CO2. After washing with PBS/Tween 20,
plates were incubated with biotinylated anticytokine Ab (1:1,000
dilution) for 2 h at 37 C. Plates were washed and incubated with
alkaline phosphatase avidin (1:5,000 dilution) for 1 h at room
temperature. Plates were developed using 5-bromo-4-chloro-3-
indolylphosphate-agarose and spots were counted the next day
using an inverted microscope. The CCCA assay was performed as
previously described (45). In brief, 10  g biotinylated anti–
IFN-  or anti–IL-4 mAbs were injected intravenously into
9-wk–infected mice. Mice were bled 18 h later and serum was
collected for the detection of IFN-  and IL-4 by ELISA.
Serum Ab Isotype Analysis. Isotype-specific Ab titers were
evaluated by indirect ELISA. Immulon 4 plates were coated with
10  g/ml SEA (50  l/well) diluted in PBS and serum samples
were analyzed using serial twofold dilutions. Second step horse-
radish peroxidase–conjugated rabbit anti–mouse IgM, IgG, IgG1,
IgG2a, and IgG2b Abs (Zymed Laboratories) were used at a
1:1,000 dilution. The absorbance was read at 405 nm using a
Vmax Kinetic Microplate Reader (Molecular Devices) after add-
ing 100  l ABTS/H2O2 one step substrate.
Statistics. Hepatic fibrosis (adjusted for egg number) decreases
with increasing intensity of infection (worm pairs). Therefore,
these variables were compared by analysis of covariance, using
the log of total liver eggs as the covariate and the log of hydroxy-
proline per egg. Variables that did not change with infection in-
tensity were compared by one way ANOVA or by Student’s t
test. Changes in cytokine mRNA expression, ELISPOT assays,
and granuloma size were evaluated by ANOVA. Results were
considered significant where P   0.05.
Results
Transition from Acute to Chronic S. mansoni Infection Is
Characterized by Increased Fibrosis and IL-13R 2 Expression
and Decreased IL-4R  mRNA in the Liver. The progres-
sion of fibrotic liver pathology after infection with S. man-
soni cercariae was evaluated in several strains of mice after
infection (46). In addition, liver RNA was isolated so that
IL-4/IL-13 receptor mRNA expression could be exam-
ined and correlated with pathology. Eggs were deposited
by adult paired parasites starting on week 4 or 5 of infec-
tion and a subset trapped in the liver, where they trigger a
vigorous inflammatory response, peaking approximately 8
or 9 wk after infection. The egg-induced granulomatous
response is also accompanied by a marked deposition of
collagen, which continues to increase in a linear fashion
into the chronic phase of infection. In these experiments,
fibrosis was evaluated at multiple time points after infec-
tion by measuring hydroxyproline levels in the liver. As
shown in Fig. 1, all three strains developed significant fi-
brosis by week 9 and this continued to increase through 16
wk after infection.
S. mansoni–infected C57BL/6, C3H/HeN, and BALB/c
mice all display increases in IL-4 and IL-13 expression that
correlate with the development of fibrotic pathology in the
liver (7). However, changes in IL-4 and IL-13 receptor ex-
pression could also affect the activity of these cytokines.
Therefore, in the following experiments, we investigated
whether IL-4R ,  c, IL-13R 1, and IL-13R 2 mRNA
expression was regulated in the liver after infection with S.
mansoni. Liver RNA was isolated at multiple time points af-
ter infection and RT-PCR analysis was performed. The
IL-13R 1 chain, which binds IL-4 and IL-13 with equal
affinity (26), was expressed constitutively in the liver of all
uninfected mice (unpublished data). Although there was
some indication that levels were decreasing slightly, partic-
ularly at the acute stage after infection in BALB/c and
C3H/HeN mice, in general, expression remained relatively
constant through week 16 (Fig. 2 D). The common  
chain exhibited a similar profile in all three strains, showing
little or no change in expression after infection (Fig. 2 C).
In marked contrast, however, results for the IL-4R  and
IL-13R 2 chains were striking. The IL-13R 2 chain was
expressed at very low levels in the liver at early stages of in-
fection. However, by the acute stage after infection, a
marked increase in IL-13R 2 mRNA expression was ob-
served in all three strains, which peaked on week 12 and
declined slightly by week 16 (Fig. 2 B). In contrast to the
IL-13R 2 chain, the IL-4R  chain exhibited an opposite
pattern of expression after infection (Fig. 2 A). A high level
of IL-4R 1 mRNA expression was observed in the liver
before the onset of egg laying, but was down-regulated on
week 9 and remained at relatively low levels throughout
the 16 wk of study. The pattern was similar in all three
Figure 1. Kinetics of hepatic fibrosis af-
ter infection with S. mansoni. Groups of
C57BL/6, BALB/c, and C3H/HeN
mice were infected with 25–30 S. mansoni
cercariae. 5–10 animals per group were
killed at the time points specified. Fibrosis
was assessed by the amount of hydroxy-
proline in micromoles detected in the
liver per worm pair. Each data point
shows the average values per group   SE.T
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strains. When viewed together, these data demonstrate that
the increasing level of hepatic fibrosis observed in chronic
infection (Fig. 1) correlates most closely with an increase in
IL-13R 2 expression.
IL-13R 2 Production Is Controlled by the Type 1/Type 2
Cytokine Expression Profile. Because expression of IL-
13R 2 correlated with the development of fibrosis, we
were interested in understanding the mechanisms that con-
trol its expression. In particular, we examined whether type
1 or type 2 cytokines influence expression of the receptor.
In previous studies, we showed that IL-10/IL-4– and IL-
10/IL-12–deficient mice develop exaggerated and highly
polarized type 1 and type 2 cytokine responses, respectively,
after infection with S. mansoni (39). As such, these mice
provided ideal tools to examine the role of cytokines in the
regulation of the IL-13R 2 chain during an ongoing in-
flammatory response. In these experiments, single and dou-
ble cytokine-deficient mice were infected and expression of
IL-13R 2 mRNA was examined in the liver. Of interest,
the only mice that failed to show a significant up-regulation
of receptor expression after infection were the IL-10 and
IL-10/IL-4 double deficient mice (Fig. 3 A). These mice, in
contrast to the other animals, showed either a mixed Th1/
Th2 or highly polarized Th1-type response after infection,
respectively (6), suggesting that a response skewed toward
Th2 cytokines is required for IL-13R 2 expression.
To further test this hypothesis, we sensitized WT
C57BL/6 mice with eggs and IL-12 before infection to de-
viate the normal egg-induced Th2 response to a more
Th1-dominant reaction (9, 47). In addition, to evaluate the
contribution of IFN-  specifically, we conducted similar
immune deviation experiments in IFN- –deficient mice.
Consistent with results generated in IL-10 and IL-10/IL-4–
deficient mice, the egg/IL-12–sensitized WT mice showed
more than a sixfold reduction in IL-13R 2 mRNA ex-
pression when compared with nonsensitized WT controls
(Fig. 3 B). Although non–IL-12–treated IFN- –deficient
mice also displayed a partial reduction (less than twofold),
the suppressive effect mediated by IL-12 was almost com-
pletely ablated in the KO animals. Cytokine assays con-
firmed that type 2 cytokine expression, including IL-4, IL-5,
and IL-13, was reduced whereas IFN-  mRNA expression
increased in the livers of the egg/IL-12–sensitized WT
mice (unpublished data). To further dissect the individual
roles of IFN-  and IL-12, additional studies were also con-
ducted in the primary lung granuloma model (47), where
the initial induction of IL-13R 2 expression could be ex-
amined. In these studies, purified eggs were injected intra-
venously into WT and IFN- –deficient mice and IL-
13R 2 mRNA expression was monitored in the lung by
Figure 2. Kinetics of IL-4/IL-13 receptor mRNA expression in the
liver after infection with S. mansoni. Groups of C57BL/6, BALB/c, and
C3H/HeN mice were infected with 25–30 S. mansoni cercariae. 5–10 an-
imals per group were killed at the time points specified. RNA was ex-
tracted from the liver of individual mice at different time points and RT-
PCR was performed as described in Materials and Methods for IL-4R 1
(A), IL-13R 2 (B),  c chain (C), and IL-13R 1 (D). Average densito-
metric units from 5 to 10 mice per time point are shown.
Figure 3. IL-13R 2 mRNA expression is regulated by the type 1/type
2 cytokine response. (A) All mice (IL-10/IL-12–deficient mice [10/
12KO], IL-12–deficient mice [12KO], WT, IL-4–deficient mice [4KO],
IL-10–deficient mice [10KO], and IL-4/IL-10–deficient mice [4/10KO])
were infected with 25–30 S. mansoni cercariae. 10 animals per group were
killed 9 wk after infection. RNA was extracted from the liver and RT-
PCR was performed for IL-13R 2. Bars, average densitometric units  
SD; *, significant difference when compared with WT values as deter-
mined by Student’s t test. P   0.05. (B) C57BL/6 (WT) and IFN- –
deficient (GKO) mice were sensitized with eggs and IL-12 (egg/IL-12) or
not and infected with cercariae as described in Materials and Methods. On
week 9, mice were killed and IL-13R 2 mRNA levels were determined
in the liver by real-time PCR. *, significant difference when compared
with the respective non–IL-12–treated control group as determined by
Student’s t test. P   0.05. (C) Naive C57BL/6 (WT) and IFN- –defi-
cient (GKO) mice were injected intravenously with 5,000 schistosome
eggs and treated with saline (filled bars) or IL-12 (open bars) as described
in Materials and Methods. Mice were killed on days 0, 7, and 11 after
challenge and total lung RNA was isolated for the detection of IL-13R 2
mRNA by real-time PCR. *, significant difference when compared with
the respective non–IL-12–treated control group as determined by Stu-
dent’s t test. P   0.05.T
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real-time PCR at 0, 7, and 11 d after challenge. Some
groups were also treated with rIL-12 during the first week.
On day 11 (Fig. 3 C), the results closely mirrored the pat-
tern observed in the liver of infected mice (Fig. 3 B), with
WT and IFN- –deficient mice showing significantly up-
regulated IL-13R 2 expression and only WT mice show-
ing reduced expression after rIL-12 treatment. Strikingly
however, on day 7, 1 d after the last treatment with rIL-12,
the non–IL-12–treated IFN- –deficient mice displayed an
enhanced IL-13R 2 response whereas WT and IFN- –
deficient mice both showed reduced IL-13R 2 mRNA
levels after treatment with IL-12. These later findings indi-
cate that IL-12 exhibits some suppressive activity that is
IFN-  independent. Nevertheless, this activity appears to
be transient because no suppression was observed in the
IFN- –deficient mice on day 11, 5 d after the last treat-
ment with IL-12.
Finally, in another series of experiments, we examined
whether the ligand for IL-13R 2 was itself a stimulus for
receptor expression. In one experiment, WT and IL-13–
deficient mice were infected with S. mansoni and IL-
13R 2 mRNA expression was evaluated in the liver tis-
sues. As shown in Fig. 4 A, IL-13R 2 expression decreased
by  80% in the absence of IL-13. Finally, a more direct
approach was used to determine whether recombinant IL-
13 alone could induce IL-13R 2 expression in the liver. In
these experiments, naive WT mice were injected with a
single dose of rIL-13 administered intraperitoneally and re-
ceptor expression was monitored in the liver at several time
points. As shown in Fig. 4 B, receptor expression was up-
regulated as early as 3 h after injection. In the example
shown, peak expression occurred at 6 h and declined there-
after. Additional studies, however, showed that IL-13R 2
expression remained above basal levels for as long as 72 h
after exposure to rIL-13 (unpublished data).
IL-13R 2 can also be released from the surface of cells
and exist as a soluble form in the serum (48). To determine
whether the soluble form of the receptor was produced af-
ter infection, Western blots were performed on sera ob-
tained from infected and uninfected WT and IL-13/IL-4–
and Stat6-deficient mice. As shown in Fig. 4 C, lane 1
shows control staining for both the membrane and soluble
forms of the receptor (arrows). Unlabeled murine IL-13
was also used as a competitor during the immunoprecipita-
tion step to demonstrate the specificity of the reaction (Fig.
4 C, lane 2). Interestingly, a low but detectable level of sol-
uble receptor was found in the serum of all uninfected mice
(Fig. 4 C, lanes 4, 6, and 8). However, only WT mice
showed a markedly increased level of the soluble form after
infection (Fig. 4 C, lane 3), further suggesting that IL-
13R 2 expression is highly dependent upon IL-4/IL-13–
and Stat6-dependent signaling pathways.
In situ hybridization was also performed on liver sections
prepared from 9-wk–infected mice so that the pattern of
expression of IL-13R 2, IL-13R 1, and IL-4R  might be
determined. As shown in the photomicrographs (Fig. 5), all
three receptors showed a unique pattern of expression in
the liver. Staining for IL-4R  was primarily restricted to
the granulomas where lymphocytes are concentrated (Fig.
5 A) whereas staining for IL-13R 2 was observed more
densely at the periphery of the lesions where fibroblast pro-
liferation and activation occurs (C). Positive staining for
IL-13R 1, in contrast to the other receptors, was much
more ubiquitous in the liver and not necessarily restricted
to the granulomatous lesions (Fig. 5 E). Control probes for
each receptor confirmed the specificity of the staining (Fig.
5, B, D, and F).
Evidence of Decoy Activity: IL-13R 2–deficient Mice De-
velop Severe Liver Fibrosis after Infection with S. mansoni. IL-
13R 2–deficient mice were generated as previously de-
scribed (38) so that the functional role of the endogenous
IL-13R 2 could be elucidated in vivo. Animals back-
crossed to the C57BL/6 and BALB/c backgrounds were
infected percutaneously with 25 S. mansoni cercariae and
examined for several immunologic and parasitologic
changes at the time of death. Because some studies sug-
gested that the immune status of the mouse may affect the
development and/or fecundity of worms (49, 50), we first
determined whether worm or egg burdens were affected
by the IL-13R 2 deficiency (Table I). Mice from both
Figure 4. (A) WT (WT F2)
and IL-13–deficient (IL-13KO)
mice were infected with 25–30
S. mansoni cercariae and 10 ani-
mals per group were killed 9 wk
after infection. RNA was ex-
tracted from the liver and RT-
PCR was performed for IL-
13R 2.  *, significant difference
when compared with WT values
as determined by Student’s t test.
P   0.05. (B) Naive C57BL/6
mice were injected with a single
10- g dose of rIL-13 and liver RNA was prepared at the various time
points indicated to determine the level of IL-13R 2 mRNA expression.
The shaded bar denotes the background levels observed in unexposed
mice. Average densitometric unit per group   SD is shown at each time
point (n   5 mice/time point). (C) Immunoprecipitation/Western of sera
from schistosome-infected and -uninfected mice. Mice (IL-4/IL-13–defi-
cient mice [IL4/13 KO], Stat6-deficient [B6 Stat6KO], and WT) were
infected with 25–30 S. mansoni cercariae and serum was collected 9 wk
after infection. All sera were precipitated with biotinylated murine IL-13
and streptavidin agarose beads overnight. The sample was treated with
PNGase F, resolved on 12% reducing gel, blotted to polyvinylidene diflu-
oride, and then IL-13R 2 detected with rabbit anti–mouse A25 and goat
anti–rabbit horseradish peroxidase. Comp, competition during the immu-
noprecipitation step with unlabeled murine IL-13 (note, no IL-13R 2
[A25] band); arrows, soluble and membrane A25 (IL-13R 2) have two
different mobilities.T
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backgrounds were perfused at the time of death, and worm
pairs and total worm burden were determined revealing no
differences in either parameter. We also noted no differ-
ence in the tissue egg burden (Table I). Liver sections from
infected WT and IL-13R 2–deficient mice were also ex-
amined microscopically for granuloma size and recruitment
of eosinophils and mast cells to the lesions (Fig. 6). Al-
though the C57BL/6 and BALB/c strains showed differ-
ences in the number of recruited eosinophils (Fig. 6 B) and
mast cells (C), there were no significant differences ob-
served between the WT and IL-13R 2–deficient mice on
either background. This was also true for macrophages and
lymphocytes, which made up 35.3 and 7.55% of granuloma
cells in WT C57BL/6 mice and 40.8 and 8.2% in IL-
13R 2–deficient mice, respectively. Similar findings were
observed with BALB/c WT and IL-13R 2–deficient mice
(unpublished data). Extensive flow cytometric analyses of
isolated granuloma cells also revealed no major differences
between the KO and WT mice (unpublished data). The
average size of granulomas was also completely unaffected
by the IL-13R 2 deficiency (Fig. 6 A).
The extent of hepatic fibrosis after infection was also as-
sessed by measuring hydroxyproline levels in the liver (Fig.
7) and staining tissue sections with the collagen-specific
Figure 5. Localization of IL-4/IL-13
receptor expression in the livers of in-
fected mice. Liver sections from 9-wk–
infected BALB/c mice were fixed in
paraformaldehyde and in situ hybridiza-
tion was performed for IL-4R , IL-
13R 2, and IL-13R 1 mRNA. Anti-
sense (A, C, and E) and sense strand (B,
D, and F) riboprobes were used in the
hybridization reaction using serial tissue
sections. The brown areas denote posi-
tive staining for each receptor. Each sec-
tion contains at least one granuloma
with a miracidium-containing egg at the
center.  20.
Table I. Parasitological Measurements in WT and
IL-13-R 2–deficient Mice at Week 9 after Infection
Total worms Worm pairs
Eggs/worm
pair ( 1,000)
N (SEM) N (SEM) N (SEM)
BALB/c WT 12.8 (1.05) 5.25 (0.5) 9.81 (1.49)
IL-13R 2 KO 11.4 (1.46) 4.30 (0.86) 9.42 (0.77)
C57BL/6 WT 19.1 (2.32) 9.40 (1.1) 5.78 (0.42)
IL-13R 2 KO 16.0 (1.92) 6.50 (1.2) 6.32 (0.78)
All data are means for each group   SEM.
N, number.T
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stain picrosirius red (unpublished data). Strikingly, both
approaches showed that IL-13R 2–deficient mice on ei-
ther background were much more susceptible to the de-
velopment of fibrosis compared to the respective WT
strains. Even more interesting was the pattern of fibrosis in
the IL-13R 2–deficient mice. In WT animals, picrosirius
red staining was largely restricted to the areas surrounding
the granulomas. The IL-13R 2–deficient mice, on the
other hand, showed a pattern of fibrosis that extended well
beyond the boundaries of the granuloma. Indeed, intense
staining was easily observed in infected IL-13R 2–defi-
cient mice in areas of the liver where no egg-induced le-
sion formation was obvious. No such staining was seen in
the parenchymal tissues of infected WT animals at this
time point.
To compliment the hydroxyproline data and to further
investigate the mechanisms involved, we examined the
mRNA expression profiles of several genes that are
thought to be directly involved in the fibrotic process.
These included procollagen I, matrix metalloproteinase
12, tissue inhibitor of matrix metalloproteinase 1, TGF-
 1, as well as arginase 1 (51–53), which is induced by IL-
4/IL-13 and regulates proline production in macrophages
(53, 54). Consistent with the increase in liver hydroxypro-
line, the IL-13R 2–deficient mice displayed a threefold
increase in procollagen I mRNA expression when com-
pared with WT mice 12 wk after infection. Tissue inhibi-
tor of matrix metalloproteinase 1 mRNA expression was
also significantly elevated whereas expression of matrix
metalloproteinase 12 mRNA decreased nearly threefold
relative to WT mice. TGF- 1 mRNA expression was
similar in both groups (unpublished data). Finally, prelimi-
nary studies examining arginase 1 revealed a two- to four-
fold increase in pulmonary arginase 1 mRNA levels in the
KO versus WT mice after an intravenous challenge with
schistosome eggs, further confirming the conclusion that
the profibrotic activity of IL-13 is increasing in the ab-
sence of the IL-13R 2.
Severe Fibrotic Response in IL-13R 2–deficient Mice Is Not
Associated with Increased Type 2 Cytokine Production. Nu-
merous studies have shown that development of fibrosis in
murine schistosomiasis is highly type 2 cytokine dependent
(6, 9, 55) and recent studies have identified IL-13 as the
key fibrogenic mediator (7, 11, 12). As such, increased IL-
4/IL-13 production could be one mechanism by which fi-
brogenesis is altered in the absence of IL-13R 2 because
signaling through the type I and type II IL-4/IL-13 recep-
tors would remain intact in these animals. Therefore, we
examined the type 1/type 2 cytokine profile both locally
and systemically in WT and IL-13R 2–deficient mice after
infection. ELISPOT assays performed on splenocytes,
however, showed no significant change in the frequency of
SEA-specific IFN- –, IL-4–, IL-5–, or IL-13–producing
cells (unpublished data). IFN-  and IL-4 levels were also
examined in the serum of infected mice using the CCCA
and Luminex assays (45, 56), however, no significant dif-
ferences were detected between the WT and IL-13R 2–
deficient mice. IL-4 was just at the threshold of detection
in most animals whereas a low but significant IFN-  re-
sponse (WT average, 52.6 pg/ml and IL-13R 2 KO aver-
age, 29.6 pg/ml) was observed in both groups. The local
cytokine response was also examined in the granulomatous
tissues by RT-PCR. Here, IFN-  mRNA expression was
again unaffected by the absence of IL-13R 2 whereas, un-
expectedly, expression of both IL-4 and IL-13 decreased
significantly (Fig. 8 A). We also examined whether expres-
sion of the IL-4/IL-13 receptor chains was altered in
the  IL-13R 2–deficient mice. As expected, IL-13R 2
mRNA expression significantly increased in WT mice after
infection whereas no IL-13R 2 mRNA was detectable in
the KO mice (Fig. 8 B). Consistent with earlier findings,
high levels of IL-13R 1 and  c were observed in both un-
Figure 6. IL-13R 2 deficiency does not affect the size or cellular com-
position of granulomas. C57BL/6 and BALB/c WT and IL-13R 2–defi-
cient mice were infected with 25–30 cercariae. Granuloma size (A), tissue
eosinophilia (B), and mast cell index (C) were assessed 9 wk after infec-
tion. Six to eight mice were included in each group and the values for in-
dividual animals are shown. Bars denote the means. No significant differ-
ences were noted.
Figure 7. Hepatic fibrosis increases in the absence IL-13R 2. (A)
C57BL/6 and (B) BALB/c WT and IL-13R 2–deficient mice were in-
fected with 25–30 cercariae and hepatic fibrosis was assessed by hydroxy-
proline assay 9 wk after infection. Six to eight mice were included in each
group and the values for individual animals are shown. Bars, the means; *,
significant difference when compared with WT values as determined by
ANOVA. P   0.05.T
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infected (not depicted) and infected mice (Fig. 8 B), and
there was no evidence that either gene was affected by the
absence of IL-13R 2. The same finding was true for IL-
4R  mRNA, although expression of this receptor gene
was found at elevated but lower levels than the other re-
ceptor chains at this postinfection time point.
The egg-specific antibody response was also examined in
the serum of infected WT and IL-13R 2–deficient mice.
Both groups showed similar titers of total anti–SEA-specific
Ig (Fig. 9). IgM titers were also similar in both animals
whereas IgG2a and IgG2b titers decreased slightly but not
significantly in IL-13R 2–deficient versus WT mice. We
did, however, note a consistent and highly significant de-
crease in the IgG1 antibody titer in receptor-deficient ani-
mals (Fig. 9) whereas levels of SEA-specific IgE were un-
changed (not depicted).
Decoy Function Is Restored and Fibrosis Decreased in IL-
13R 2–deficient Mice after Administration of sIL-13R 2-Fc
Protein. In a final series of experiments, a soluble IL-13
antagonist composed of the IL-13R 2 chain (29) was
administered to IL-13R 2–deficient mice to determine
whether the increase in hepatic fibrosis observed in recep-
tor-deficient animals could be reversed by restoring IL-
13R 2 activity. In these experiments, IL-13R 2–deficient
mice were infected for 12 wk and treated with sIL-13R 2-
Fc or control-Fc protein for 6 wk after the onset of egg
laying (weeks 6–12). Thus, in contrast to previous experi-
ments, these studies examined the function of the decoy re-
ceptor at a more chronic time point after infection. Be-
cause the RT-PCR results presented above (Fig. 8 A) show
decreasing levels of IL-13 mRNA in IL-13R 2–deficient
versus WT mice, we initially examined whether the decoy
receptor was influencing IL-13 expression in serum. Inter-
estingly, quite high levels of IL-13 were detectable in in-
fected WT mice (Fig. 10 B) whereas  50 pg/ml IL-13 was
observed in uninfected mouse serum (not depicted). Con-
sistent with results in the liver, the levels of IL-13 protein
were much lower in IL-13R 2–deficient animals. Strik-
ingly, however, serum levels of IL-13 increased dramati-
cally when the KO mice were treated with the sIL-
13R 2-Fc protein. Consistent with findings from acute
time points (Fig. 7), mice deficient in IL-13R 2 again de-
veloped significantly more fibrosis than infected WT ani-
mals (Fig. 10 A). Of more importance, however, fibrosis
markedly decreased when the sIL-13R 2-Fc protein was
administered, falling to levels that were even lower than
those observed in untreated WT mice.
Discussion
Many parasitic helminths induce highly polarized type 2
cytokine responses in their hosts and these responses con-
trol a variety of important functional activities including
parasite expulsion (17–19), eosinophil activation (57), and
development of fibrosis (11, 58). In schistosomiasis, the
type 2 cytokine response is primarily directed at the parasite
eggs (59) and studies have shown that much of the egg-
induced liver pathology is controlled by the relative domi-
nance of type 1 versus type 2 cytokine expression (9, 55).
Although it is clear that development of an egg-specific
CD4  Th2-type response is critical for normal granuloma
formation (55) and host survival after infection (60, 61), if
these responses are too vigorous or persist for too long they
can become detrimental and even lethal to the infected
host (5, 6). Of the type 2 cytokines examined to date, IL-
13 appears to be particularly important because studies
show that mice deficient in this cytokine survive longer
(12) and fail to develop the fibrotic tissue pathology seen in
Figure 8. IL-4 and IL-13 mRNA expression decreases in IL-13R 2–
deficient mice. (A) WT C57BL/6 (open bars) and IL-13R 2–deficient
(filled bars) mice were infected with 25–30 cercariae. RT-PCR was per-
formed for IL-4, IL-13, and IFN-  on liver tissues as described in Materi-
als and Methods. *, significant difference when compared with WT
values as determined by Student’s t test. P   0.05. (B) RT-PCR for IL-
13R 1, IL-13R 2, IL-4R , and  c chains was performed on the same
tissues. Six to eight mice were killed per group and the average arbitrary
densitometric units are shown   SD. No significant differences were
found between the WT and IL-13R 2–deficient mice. Similar results
were obtained with tissues from mice on the BALB/c background.
Figure 9. SEA-specific IgG1  ti-
ters decrease in IL-13R 2–defi-
cient mice. S. mansoni egg-specific
antibody levels were measured in
sera of infected WT and IL-
13R 2–deficient mice (C57BL/6)
9 wk after infection as described in
Materials and Methods. Bars from
bottom to top show the 10th, 25th,
50th, 75th, and 90th percentiles, re-
spectively, of the tested samples.
Single outliners are indicated as cir-
cles. Data were obtained from
groups of mice containing 6–8 mice/group. *, significant difference when compared with WT values as determined by Student’s t test. P   0.05.
Note that IgG1 is the predominant egg-specific Ig isotype detected in serum.T
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chronic S. mansoni infection (7, 11). Therefore, to better
understand disease pathogenesis, it is important to elucidate
the mechanisms that control production of IL-13 and/or
limit its various effector functions in vivo.
Although IL-4 and IL-13 share many functional activi-
ties, we hypothesized that the pathogenic effects of IL-13
are more marked than those of IL-4 because more IL-13 is
produced during S. mansoni infection (11). Indeed, our
studies suggested that IL-13 production is nearly 100-fold
greater than IL-4 at the site of granuloma formation. This
may in part be explained by the kinetics of the response be-
cause IL-4 production is only transiently expressed after
egg exposure whereas production of IL-13 is more rapid
and sustained over a longer time period (42). Thus, ligand
availability is clearly one mechanism regulating the func-
tional activities of these cytokines in vivo. Nevertheless,
the pattern of IL-4/IL-13 receptor expression in the liver
could be an equally important regulatory mechanism. Be-
fore this study, however, there was relatively little known
about the IL-4–IL-13 receptor complex and whether ex-
pression of the four unique receptor subunits was regulated
during infection.
Previous studies showed that IL-13 mRNA expression is
induced rapidly after infection, with peak expression oc-
curring in the liver on week 9 and remaining at relatively
high levels through 16 wk after infection (7). This work,
examining the regulation of the IL-4R ,  c, IL-13R 1,
and IL-13R 2 genes, suggests a much more intriguing pat-
tern of expression of the IL-4–IL-13 receptor complex in
schistosomiasis. Although the  c and IL-13R 1 chains
showed little evidence of regulation, the signaling IL-4R 
chain and decoy IL-13R 2 were highly regulated and dis-
played an opposite pattern of expression in the liver. IL-
4R  mRNA expression was high at early time points and
showed little regulation before the onset of egg laying.
However, by week 9,  4 wk after egg laying commences,
mRNA levels decreased markedly and remained at low but
detectable levels through 16 wk after infection. In contrast,
IL-13R 2 mRNA was almost undetectable at early time
points but was up-regulated after egg deposition. In situ
hybridization for the three unique IL-4/IL-13–specific re-
ceptors showed significant expression of all three receptors
throughout the liver of infected mice. IL-13R 1 was ex-
pressed ubiquitously whereas the IL-4R  chain was found
at higher levels within the granuloma and the IL-13R 2
localized at the periphery. Because IL-13R 2 followed a
pattern that closely mirrored the development of hepatic fi-
brosis, we examined both the regulation and functional ac-
tivity of the decoy IL-13 receptor in more detail.
Induction of IL-13R 2 expression during infection co-
incides with the emergence of the egg-specific type 2 cy-
tokine response (59). Therefore, we were initially inter-
ested in knowing whether type 1 or type 2 cytokines
influence receptor up-regulation after infection. Experi-
ments in several cytokine-deficient mice suggested that IL-
10 and IL-13 are important mediators of IL-13R 2
mRNA expression. The effects of IL-10, however, appear
to be indirect because mice deficient in both IL-10 and IL-
12 showed no reduction in IL-13R 2 expression. This was
in contrast to IL-10 and IL-10/IL-4–deficient mice, which
displayed impaired receptor up-regulation. Because IL-10
and IL-10/IL-4–deficient mice develop strong IFN-  re-
sponses, whereas IL-10/IL-12–deficient mice display polar-
ized type 2 cytokine responses (39), these data suggest that
IL-10 regulates receptor expression by modulating the
dominance of type 1/type 2 cytokine expression. This con-
clusion was strengthened by our immune deviation studies
(Fig. 3 B) in which expression of the decoy receptor was
clearly reduced in mice exposed to the Th1-inducing adju-
vant IL-12. Moreover, immune deviation studies con-
ducted in IFN- –deficient mice suggested that the suppres-
sive effects of IL-12 were largely IFN-  dependent.
Of even more interest, studies conducted in IL-13–defi-
cient mice demonstrated a critical role for the ligand of the
IL-13R 2 in receptor expression. In contrast to IL-10,
these experiments suggest IL-13 acts more directly because
exogenous administration of rIL-13 alone rapidly induced
IL-13R 2 mRNA expression in the liver (Fig. 4 B). Levels
of IL-13R 2 also increased in the serum after infection and
expression was clearly dependent on IL-4/IL-13 and Stat6-
dependent signaling pathways (Fig. 4 C), further emphasiz-
ing the importance of type 2 cytokine responses for decoy
receptor production. The finding that receptor levels were
markedly reduced in IL-13–deficient mice (Fig. 4 A) yet
Figure 10. Exacerbated fibrotic response of IL-13R 2–deficient mice
is prevented by administration of sIL-13R 2-Fc. WT BALB/c and IL-
13R 2–deficient mice were infected with 25–30 cercariae. Beginning on
week 6, IL-13R 2–deficient mice were treated with sIL-13R 2-Fc or
control Ig (200  g every other day) for a total of 6 wk. All animals were
killed on week 12 and fibrosis (A) and serum levels of IL-13 (B) were de-
termined. The values shown are mean values   SEM for WT (n   10),
IL-13R 2 KO (n   10), and sIL-13R 2-Fc–treated IL-13R 2 KO mice
(n   15). The P values, as determined by ANOVA, are shown in A. In B:
*, significant difference when compared with the WT group as deter-
mined by Student’s t test. P   0.05.T
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not significantly altered in IL-4–deficient animals (Fig. 3 A)
also suggests IL-13 might be the primary type 2 cytokine
stimulating IL-13R 2 expression. Thus, although it is con-
ceivable that rIL-4 and rIL-13 (Fig. 4 B) would both ex-
hibit IL-13R 2–inducing activity, IL-13 is likely the more
important endogenous inducer simply because it is over-
produced relative to IL-4 during infection (11).
In a recent paper examining the regulation of the IL-
13R 2 in human monocytes, Daines and Hershey (62)
showed that IL-13R 2 is rapidly mobilized from intracel-
lular stores to the cell surface after treatment with IFN- .
The authors hypothesized that induction of IL-13R 2 ex-
pression by IFN-  might represent a novel mechanism to
regulate IL-13 responses. Surprisingly, our data, gathered
mostly from in vivo studies, fails to support this hypothesis,
which might be explained by the different models being
investigated. Alternatively, it may simply indicate that dif-
ferent regulatory mechanisms are exhibited by whole tis-
sues (this study) versus cells stimulated in vitro (62). Our
findings demonstrate that the decoy receptor is up-regu-
lated to the greatest extent during polarized Th2 responses.
IL-13R 2 expression was highly IL-13/IL-4–, IL-4R–,
and Stat6-dependent. Except for the small twofold decrease
observed in the livers of infected IFN- –deficient mice,
there was no evidence that IFN-  was required for recep-
tor up-regulation. On the contrary, mice polarized to a
Th1-dominant response via treatment with rIL-12 showed
decreased IL-13R 2 expression. This IL-12–induced inhi-
bition of IL-13R 2 was largely dependent on IFN-  be-
cause in the liver IL-12 failed to reduce receptor expression
in IFN-  KO mice, further highlighting the down-regula-
tory (rather than up-regulatory) role of IFN-  in receptor
expression. As such, our in vivo data suggest a different
regulatory mechanism for the IL-13R 2 than that pro-
posed by Daines and Hershey (62). Instead of a cross-regu-
latory system where IFN-  drives IL-13R 2 expression to
attenuate IL-13 activity, our studies suggest that IL-13R 2
is a negative feedback mechanism induced by the Th2 re-
sponse itself. Interestingly, given that this system would act
in an antigen-nonspecific way to attenuate IL-13 activity,
this mechanism of helminth-induced IL-13R 2 expression
could, at least in part, also provide an explanation for the
hygiene hypothesis, which suggests that the increase in al-
lergic disease observed in westernized countries is due to
decreased exposure to childhood infections (63). Our find-
ings demonstrate that schistosome infection provides a po-
tent stimulus for decoy receptor expression, which presum-
ably could act as a bystander mechanism to neutralize the
allergy-inducing potential of IL-13.
Although expression of the IL-13R 2 correlated with
development of fibrosis (Fig. 2 B), the role of the endoge-
nous IL-13R 2 remained hypothetical until KO studies
could be conducted. In previous work, we showed that ad-
ministration of sIL-13R 2-Fc fusion protein was highly ef-
ficacious for the prevention of fibrotic liver pathology (11).
Moreover, recent studies demonstrated that IL-13 antago-
nism could also be used to block the progression of estab-
lished disease (7). As such, these findings suggest that a pri-
mary function of the IL-13R 2 is to inhibit the profibrotic
activity of IL-13. To directly test this hypothesis and evalu-
ate the function of the endogenous IL-13R 2, we infected
mice with a targeted deletion of IL-13R 2 (38). Strikingly,
hepatic fibrosis increased significantly in IL-13R 2–defi-
cient mice. Importantly, these data were reproducible in
KO mice generated on two different genetic backgrounds,
providing one of the first in vivo examples of functional
decoy activity for the endogenous IL-13R 2.
The pattern of liver fibrosis in the IL-13R 2–deficient
animals was also quite intriguing. Although fibrosis in WT
mice was primarily restricted to the areas surrounding the
developing granulomas, collagen staining in the KO mice
extended beyond the areas of lesion formation and ap-
peared to spread throughout the liver parenchyma itself.
These data suggest that the protective function of the de-
coy receptor might extend to areas not directly affected by
the parasite eggs. Nevertheless, the exacerbated fibrotic re-
sponse appeared to be restricted to the liver because hy-
droxyproline assays performed on kidney, lung, and brain
of infected IL-13R 2–deficient mice showed no evidence
of excess collagen deposition in these nongranulomatous
tissues (unpublished data). These findings are important be-
cause nanogram quantities of IL-13 are detectable in the se-
rum of infected mice (Fig. 10 B) and the absence of decoy
receptor could trigger fibrogenesis in tissues not directly af-
fected by the parasite eggs. In some S. mansoni–infected
humans, pipe stem fibrosis along the hepatic portal tracks is
not necessarily associated with the egg-induced granulomas
(64). It is intriguing to speculate that if the IL-13R 2 ex-
hibits similar protective activity in humans, it might repre-
sent an important mechanism to prevent fibrosis at distant
sites within the liver.
Markedly, the increase in hepatic fibrosis in IL-13R 2–
deficient mice on week 9 was not accompanied by any ob-
vious change in the size nor cellular composition of the
granulomas. Similar findings were also reported in infected
IL-13R 2-Fc–treated (11) and IL-13–deficient mice (12).
In each of these studies, granulomatous inflammation was
regulated by the combined actions of IL-4 and IL-13
whereas fibrosis was regulated primarily by IL-13. Thus,
the primary function of IL-13 and its receptors appears to
be the regulation of fibrosis. Hepatic fibrosis in schistoso-
miasis is also tightly controlled by the relative dominance of
IFN-  versus IL-13 produced locally in the liver (7). In-
deed, studies showed that mice that produce high levels of
IL-13 and low levels of IFN-  develop much more severe
fibrosis than animals that have a high IFN- /IL-13 ratio (5,
65). Therefore, we were interested in knowing whether
changes in type 1/type 2 cytokine dominance were con-
tributing to the exacerbated fibrotic response. Strikingly,
however, our findings suggested that type 2 cytokine ex-
pression was actually decreasing in the livers of the KO an-
imals (Fig. 8). This conclusion was strengthened by analyz-
ing serum levels of IL-13, which were also markedly
reduced in the IL-13R 2–deficient mice (Fig. 10). Finally,
decreasing levels of egg-specific IgG1 Abs (the dominant
Ab isotype expressed during infection) provided additionalT
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
698 In Vivo Regulation and Function of the IL-13 Receptor   2
evidence of a general decline in type 2 cytokine expression
(Fig. 9). Thus, fibrosis increases in the IL-13R 2 KO mice
despite the significant decrease in IL-13 levels. Importantly,
expression of IL-13R 1 and IL-4R  mRNA chains did
not differ in the WT and IL-13R 2–deficient mice, which
may explain why IL-13 remains active in both animals.
These results suggest that even reduced levels of IL-13 are
sufficient to generate significant fibrosis when IL-13R 2
expression is low or absent. As such, these findings add ad-
ditional weight to the importance of the IL-13R 2 in the
regulation of type 2 immune responses because they clearly
demonstrate an enhancement of IL-13 activity in the ab-
sence of the decoy receptor. The results also suggest the
decoy receptor has a much greater influence on the devel-
opment of fibrosis than the relative level of IL-13.
The decrease in IL-13 expression in the KO mice was
particularly surprising because it is clear from both blocking
and KO studies that IL-13 is required for the development
of hepatic fibrosis in schistosomiasis (11, 12). These find-
ings suggest that a sensitive and highly regulated mecha-
nism is in place to control production of IL-13, IL-13R 2,
and development of tissue fibrosis. This elegant system for
controlling tissue pathology was best exemplified in the last
series of experiments (Fig. 10) in which IL-13R 2 activity
was restored in the KO mice by treating them with a sIL-
13R 2-Fc construct. Fibrosis more than doubled by 12 wk
after infection in the IL-13R 2–deficient mice whereas the
fibrotic response was largely prevented in the group receiv-
ing sIL-13R 2-Fc. In fact, the sIL-13R 2-Fc construct re-
duced fibrosis in the KO animals by  70%, formally dem-
onstrating that their exacerbated pattern of fibrosis was
entirely due to the absence of IL-13R 2 expression and
heightened IL-13 activity. We observed that the impaired
serum IL-13 response in the KO animals was restored and
even increased after administration of sIL-13R 2-Fc (Fig.
10). As such, these data suggest that as fibrosis increases in
IL-13R 2–deficient mice, IL-13 levels drop, perhaps to
compensate for the worsening tissue response. Similarly,
when fibrosis is reduced in the KO mice after sIL-13R -
Fc treatment, levels of the profibrotic cytokine IL-13 in-
crease in the serum. Alternatively, IL-13 may simply act as
a negative regulator of its own production. It is also possi-
ble that serum levels of IL-13 increase after sIL-13R 2-Fc
treatment because the receptor is acting as a depot or car-
rier for the cytokine, essentially extending the in vivo half-
life of IL-13 via a mechanism analogous to cytokine–anti–
cytokine antibody complexes (38, 66). Regardless of the
exact mechanisms involved, this reciprocal pattern of regu-
lation suggests that a tight balance between IL-13 and IL-
13R 2 expression might be required for the establishment
of an optimal healing response.
Th2-mediated inflammation plays a central role in the
pathogenesis of a variety of other fibrotic disorders includ-
ing asthma (29), idiopathic pulmonary fibrosis (67, 68),
chronic graft rejection (69), bleomycin-induced pulmo-
nary fibrosis (70), progressive systemic sclerosis (71), radia-
tion-induced pulmonary fibrosis (72), and hepatic fibrosis
(9, 11, 12, 73). The studies presented here document the
important protective function of the endogenous IL-
13R 2 and its role in the inhibition of IL-13–mediated
tissue fibrosis. Moreover, these studies demonstrate that
the decoy IL-13R 2 can also regulate the magnitude of
Th2-type cytokine production in vivo. As such, our find-
ings illustrate a novel and previously unappreciated mecha-
nism for limiting the pathogenesis of chronic Th2-medi-
ated inflammatory responses.
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